Other News To Note
Thursday, July 7, 2011
Threshold Pharmaceuticals Inc., of Redwood City, Calif., said the National Comprehensive Cancer Network awarded a grant to Herb Hurwitz, associate professor of medicine at the Duke Cancer Institute, to evaluate the company's hypoxia-activated prodrug, TH-302. The Duke Cancer Institute expects to begin a Phase I trial during the fourth quarter to evaluate the safety and preliminary activity of TH-302 in combination with pazopanib (Votrient) in advanced solid tumors. In March, the company raised $30 million in a registered direct offering to advance clinical trials for TH-302.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.